cyrilzakka/clinical-trials huggingface dataset:
Do Patients With Colorectal Cancer Understand That Their Family is at Risk?

The purpose of this study is to assess whether patients with colorectal cancer understand that their first-degree relatives are at increased risk of getting the cancer themselves and therefore should be screened early. Among patients who do understand the risks to their family, we plan to determine who they identify as the source of their information and whether they have acted upon this information and advised family members to be screened. We hypothesize that many patients with colorectal cancer do not have a correct understanding of the risks to their first-degree relatives and the recommendations that they be screened early.

If this hypothesis is shown to be true, it can be used to direct improved and more diligent patient education. This, in turn, will hopefully increase the low screening rates among first-degree relatives, and, thereby, save lives in this high-risk population.

1. The primary physician of patients with colorectal cancer will be contacted and asked permission to contact their patient to discuss his or her understanding of familial risk before patient is contacted.
2. A letter will be sent to all patients prior to being contacted, notifying them that all identifying information will be kept confidential and they may decline to participate at any time.
3. Patients will be called and asked a series of questions about their understanding of familial risk of colon cancer, the need for early screening and where they learned what they know. If the patient has lacking knowledge they will be educated.
4. Each patient will be sent informational brochures about colon cancer after the phone survey.
5. Six months later, the patients will be contacted again and asked a series of questions about their understanding of familial risk of colon cancer and the need for early screening to access how much impact the informational brochures had on their knowledge of cancer risk. Patients will be asked one additional demographic question about the highest level of education that they have completed.

Eligibility Criteria:
Inclusion Criteria:

Patients who were diagnosed with CRC and received first treatment here or elsewhere and patients who were diagnosed elsewhere and received their first treatment here. All are currently followed here and still alive.

Exclusion Criteria:

Patients in the registry who are not followed here, patients with Familial Adenomatous Polyposis, patients with Hereditary Non-Polyposis Colorectal Cancer, and patients with no siblings or children.
Effect of MSD on FCR Among Gastric Cancer Survivors

The goal of this clinical trial is to explores the effect of marital self disclosure intervention on fear of cancer recurrence and dyadic coping ability in gastric cancer survivors and their spouses. The main questions are: What is the level of fear of cancer recurrence among gastric cancer survivors and their spouse? What is the level of dyadic coping ability among gastric cancer survivors and their spouse?What is the effect of marital self-disclosure intervention on fear of cancer recurrence and dyadic coping ability in the gastric cancer survivors and their spouses? Participants will accept the intervention of marital self disclosure for 4 times (4 cycles of chemotherapy) with different topics. Researchers will compare with control group to see if the level of fear of cancer recurrence and dyadic coping ability will be improved.


Eligibility Criteria:
Inclusion Criteria:

* The disease meets the diagnostic criteria of "Guidelines for Diagnosis and Treatment of Gastric Cancer"(Department of Medical Affairs, 2019), the preoperative gastroscopy and pathological diagnosis are advanced gastric cancer, and the postoperative pathological classification is type II, III or IV
* Age ≥ 18 years
* Able to write and oral communicate effectively by themself
* The main caregiver is their spouse
* Clear consciousness, no understanding barriers
* Agree to participate in this study

Exclusion Criteria:

* History of receiving a structured psychological intervention from a psychiatrist or a psychologist
* Cognitive disorders or psychiatric disorders (according to the DSM-V)
* Severe visual, hearing and speech impairment
* With previous or concurrent malignant tumors
* With severe complications, such as gastrointestinal obstruction, perforation, etc.
A Randomized Controlled Trial of Geriatric Emergency Department Innovations

This study evaluates the Geriatric Emergency Department Innovations (GEDI) program at Northwestern Memorial Hospital to care for older adults in the emergency department. Half of the patients will be cared for by a standard ED team plus the GEDI team, while half of the patients will receive usual ED care.

Hospitalization is common for older adults in the Emergency Department (ED) but it carries significant risks including the development of delirium, falls, and nosocomial infections. The Geriatric Emergency Department Innovations (GEDI) program at Northwestern Memorial Hospital attempts to identify and address health related risks for older adults without exposing them to the risks of hospitalization,. GEDI is a unique program consisting of a multidisciplinary team of Transitional Care Nurses (TCN), social workers, pharmacists, occupational therapists and physical therapists who perform ED-based geriatric assessment and care coordination.

To determine the impact of GEDI on health services use and Health Related Quality-of-Life (HRQoL) we will conduct a randomized controlled trial comparing GEDI compared to usual ED care(which often involves hospitalization).

Eligibility Criteria:
Inclusion Criteria:

Northwestern Emergency Department patients who are:

* 65 years or older
* living independently or with friends, family, or caregivers in the community
* Clinical Frailty Scale (CFS) score of 4 or greater

Exclusion Criteria:

Patients will be excluded if they:

* Tested positive for COVID-19
* Are unable to complete the assessments in English
* Are unable to provide informed consent with no Legally Authorized Representative Present or are unable to complete follow-up participation
* Are held in the ED involuntarily as a prisoner or patient with a psychiatric complaint
* Are enrolled in another study to avoid patient fatigue and confounding
* Received a GEDI, Social Work, Pharmacy, or Physical Therapy consult outside of this trial during the current ED visit
* Leave the ED against medical advice or without being seen by a physician
* Are admitted to the ICU
* Are too medically unstable to participate in the assessment
Effect of LANCONONE in Weight-bearing Joint Pain

The current study has been designed to primarily assess the effect of Lanconone® in comparison to placebo on pain in weight bearing joints.


Eligibility Criteria:
Inclusion Criteria:

1. BMI ≥ 25 and ≤ 29.9 kg/m2.
2. With unilateral or bilateral OA of the knee for at least greater than 3 months, as presented by pain in the knee at least for last 3 months.
3. Post-menopausal females (LMP at least 12 months prior to the screening).

Exclusion Criteria:

1. History of osteoarthritis for more than 3 years.
2. Systolic Blood Pressure ≥140 mm Hg and Diastolic Blood Pressure ≥ 90 mm Hg
3. FBS\>140 mg/dl.
4. Smokers or chronic alcoholics.
5. Participants planning to travel in the next 56 days or engage in any non-routine activity that is likely to strain the knees.
Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment

The purpose of the study is to determine the pharmacokinetics and safety of elinogrel and its metabolite in patients with mild, moderate, and severe renal impairment compared to healthy volunteers.

Multiple-dose, open-label parallel-group design in patients with mild, moderate or severe renal impairment and age (±7 years), sex and weight (±15% BMI) matched healthy subjects.

* mild renal impairment: CrCl from 50 to ≤80 ml/min
* moderate renal impairment: CrCl from 30 to \<50 ml/min
* severe renal impairment: CrCl of \<30 ml/min

Eligibility Criteria:
Inclusion Criteria:

* Able to understand and sign the written informed consent
* Subjects should have either normal renal function or have stable renal disease

Exclusion Criteria:

* History of heart disease
* Unstable or clinically significant other disorders such as respiratory, hepatic, metabolic, psychiatric or gastrointestinal disorder
Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg

The purpose of this study is to determine whether abatacept at a dose 30 mg/kg via intravenous infusion is safe and well tolerated in the treatment of lupus nephritis in mainland Chinese subjects with systemic lupus erythematosus (SLE)


Eligibility Criteria:
Inclusion Criteria:

* Men and women, at least 18 years of age, with a diagnosis of systemic lupus erythematosus (SLE) and with lupus nephritis currently stable for the last 3 months without change in treatment for lupus nephritis
* Stable renal disease
* No flaring of other organ systems in a minimum of the last 3 months

Exclusion Criteria:

* Unstable lupus nephritis and serum creatinine \>3 mg/dL
* Progressive renal failure, end stage renal disease, or renal transplant requiring continuous dialysis
* Severe unstable, refractory, or progressive SLE
* History of cancer
* Participants at risk for tuberculosis
* Autoimmune disease other than SLE as main diagnosis
* Human immunodeficiency virus or herpes zoster infection
* Hepatitis-B surface antigen-positive or hepatitis C antibody-positive participants
Testosterone Replacement to Alleviate Pain in Postmenopausal Women (TRAPP Trial)

The aim of this trial is to evaluate whether testosterone replacement results in greater improvement in pain perception, pain tolerance, sexual function, physical function and quality of life when compared with placebo in women with chronic back pain treated with opioids who have low testosterone.

This single-center, randomized, double-blind, placebo-controlled, parallel-group trial will evaluate pain and quality of life outcomes associated with 3 months of treatment with testosterone or placebo in women aged 60 years or older with chronic non-cancer back pain who are taking opioid analgesics for at least 6 months and have low testosterone.

Eligibility Criteria:
Inclusion Criteria:

* Women, age 60 years and older.
* Chronic non-cancer back pain.
* Use of opioid analgesics for at least 6 months.
* Serum total testosterone \<8.7 ng/dL and/or free testosterone \<0.47 pg/mL.
* Normal mammogram within the last 12 months
* Endometrial thickness of \<4 mm in women with an intact uterus assessed by endometrial ultrasound.
* Ability and willingness to provide informed consent.

Exclusion Criteria:

* History of breast or endometrial cancer
* Estrogen therapy in the past 3 months
* Baseline hematocrit \>48%.
* Serum creatinine \>2.5 mg/dL.
* HbA1c \>9.0%. Subjects on insulin therapy will be excluded.
* BMI \>40 kg/m2.
* Uncontrolled congestive heart failure.
* Myocardial infarction, acute coronary syndrome, revascularization surgery or stroke within the past 3 months.
* History of genetic thromboembolic disorder.
* Diagnosis of bipolar disorder or schizophrenia.
* Use of testosterone, spironolactone, finasteride or systemic ketoconazole in the past 3 months.
Comparison of the Effects of Sacrospinous Fixation and V-notes Lateral Suspension Operations

Comparison of the effects of sacrospinous fixation and v-notes lateral suspension operations on anatomical recovery, effectiveness and quality of life in a training and research hospital gynecology and obstetrics clinic.


Eligibility Criteria:
Inclusion Criteria:

* patient aged 35-75 patients without pelvic mess, servical or endometrial lesion

Exclusion Criteria:

* patients with pelvic mess, servical or endometrial lesion patient with diagnosed endometrial cancer
Comparing Stationary and Mobile Ergospirometry

The goal of this randomized crossover trial is to compare the results of a stationary and a mobile ergospirometry system in 20 healthy endurance trained participants. The main question it aims to answer is to investigate the differences in VO2-measurements between the mobile K5 and the stationary Quark ergospirometry system.

Participants will do a maximal ramp test followed by a sub maximal step test with 6 stages on two different days.

20 endurance trained men and/or women will be recruited. A screening will be done before starting with the test protocol on the treadmill to ensure the suitability of the participants. The test protocol includes two parts. The first part is a maximal ramp test (+0.6km/h each minute until exhaustion). The second part includes a step test with 6 sub maximal stages - each lasting 5 minutes - at 50%, 55%, 60%, 70%, 75% and 80% of the maximal velocity achieved in the first part. There will be a short break between the ramp and the step test. The stationary and the mobile system are tested on 2 separate days with a break of 1-3 days in between. On the second day, procedure will be exactly the same for the participants.

Eligibility Criteria:
Inclusion Criteria:

* endurance trained (minimum two times endurance training per week)
* healthy as assessed by the physical-activity-readiness-questionnaire (PAR-Q)
* adequately informed and consent confirmed per signature

Exclusion Criteria:

* Pregnancy based on anamnesis
* acute illness, injury, infection, etc., which would impact the measurements
Clinical Trial of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to evaluate the efficacy and safety of Kanglaite Injection for advanced non-small cell lung cancer(NSCLC).

This study include a multicenter, randomized, controlled post-market clinical trial.The randomized clinical trial will enroll approximately 334 patients. Participants will be randomly divided into experimental (n=167) and control groups (n=167).Patients in the experimental group will receive Kanglaite Injection combination with first-line chemotherapy based on NCCN Guidelines (2019.V3). Patients in the control group will receive first-line chemotherapy based on NCCN Guidelines (2019.V3).The primary endpoint is PFS(progression free survival).The research protocol was approved by the relevant ethics committees, and the study was conducted according to the Declaration of Helsinki and Good Clinical Practice guidelines. Patients gave written informed consent to participate in the trial.

Eligibility Criteria:
Inclusion Criteria:

* A Histological or cytological confirmed diagnosis of Stage III-IV NSCLC, with no history of anticancer treatment including chemotherapy;
* Male or female aged 18-75years;
* Eastern Cooperative Oncology Group (ECOG) performance score 0-2;
* Life expectancy of at least 3 months;
* At least one radiographically measurable lesion per RECIST 1.1;
* Willing to join the clinic trail and sign informed consent;
* Able to comply with scheduled visits and treatments.

Exclusion Criteria:

* Presence of cerebral metastases;
* Confirmed positive for expression of expression of epidermal growth factor receptor (EGFR), activin receptor-like kinase (ALK), c-ros oncogene 1 (ROS1) mutation, or programmed death-ligand 1 (PD-L1)(tumor proportion score \[TPS≥ 50%\] in a genetic test;
* Participants with malignant pleural effusion underwent intrapleural injection chemotherapy;
* Current undergoing or preparing for treatment with target therapy;
* Current undergoing or preparing for radiotherapy to the thorax;
* Current undergoing or preparing treatment with tumor immunotherapy;
* Currently undergoing lipid-decreasing treament;
* Pregnant or breastfeeding woman;
* Fertile patients who are unwilling or unable to take effective contraceptive measures during the research period until 6 months after the study end later;
* A history of mental disorders；
* Severe and uncontrolled organic lesion or infection, including but not limited to cardiopulmonary failure and renal failure，which lead to poor tolerance of chemotherapy;
* Participated in other clinical trials of small molecule research drugs within 28 days prior to enrollment, or participated in other clinical trials of large molecule research drugs within 3 months before enrollment;
* Known allergy or intolerance to study medications;
* Considered to be otherwise unsuitable for the clinical study by researchers.
Nifedipine for Acute Tocolysis of Preterm Labor

The purpose of this study is to determine if nifedipine treatment of women in preterm labor receiving corticosteroids results in postponement of delivery when compared to placebo.


Eligibility Criteria:
Inclusion Criteria:

* Between 16 and 44 years of age inclusive
* Singleton pregnancy
* Intact membranes
* Between 28-0/7 weeks and 33-6/7 weeks' gestation inclusive
* Reported or documented uterine activity
* Cervical dilation between 2 cm and 4 cm inclusive

Exclusion Criteria:

* Multifetal gestation
* Less than 28 weeks' gestation
* 34 or more weeks' gestation
* Ruptured membranes
* More than 4 cm dilated
* Previously received a course of corticosteroids for fetal lung maturation
* Oligohydramnios
* Fetal growth restriction
* Chorioamnionitis or temperature of at least 38.0 degrees Celsius
* Fetal death
* Preeclampsia
* Suspected placental abruption or placenta previa
* Lethal fetal malformation or amniotic fluid index at least 35
* Systolic BP \< 90 mmHg or diastolic BP \< 50 mmHg
* Baseline tachycardia (pulse \>120 after 2 consecutive measurements 30 minutes apart)
* Chronic hypertension treated with antihypertensives in pregnancy
* Seizure disorder or HIV
* Maternal allergy to nifedipine
* Known maternal cardiac disease
* Women who have received progesterone therapy in the second or third trimester for prevention of preterm birth
Clinical and Dermoscopic Comparison of Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriasis Patients' Nails

This study evaluates the fingernail findings of the rheumatoid arthritis, spondylopathy and psoriatic arthritis patient groups with the fingernails of psoriasis patients clinically and dermatoscopically and investigates the benefit of dermoscopy in the differentiation of these patients.

Psoriasis is a common chronic inflammatory disease with many comorbidities. Dermatologists have a very important role in the early diagnosis of psoriatic arthritis, which is one of the most important comorbidities of psoriasis. Therefore, studies have been conducted on many factors predicting the risk of psoriatic arthritis and it has been concluded that nail involvement is closely related to psoriatic arthritis.For this reason, the importance of nail examination in the follow-up of psoriasis patients has increased significantly. Nail examination should be done carefully to predict the risk of developing psoriatic arthritis, especially at the beginning of the disease and subclinical types, and dermoscopy should be used to identify patients who may be clinically uncertain.

In addition, rheumatoid arthritis and spondylopathy patients have a lot in common with psoriatic arthritis patients.In these patients, there is no clear distinction to diagnose joint involvement, and their distinction is mostly based on the presence or absence of skin findings.Nail findings have an important place among this skin findings in the diagnosis of these patients.

Based on all these, this study questions the benefit of clinical and dermoscopic examination of nail findings in the early stages to differentiate these patients, as well as comparing the nail findings and revealing the differences and similarities.

Eligibility Criteria:
Inclusion Criteria:

* Psoriasis confirmed by dermatologist.
* Rheumatoid arthritis, ankylosing spondylitis confirmed by rheumatologist (newly diagnosed).

Exclusion Criteria:

* Unable to consent and understand
* Patients with confirmed onychomycosis
* Patients receiving biological therapy
Traumatic Proximal Femoral Fractures in Adults

Statistical analysis for adult patients who were admitted to Assiut university hospital within one year with proximal femoral fractures.

Protocol of management include lines of treatment , hospital stay and results

Case series prospective study All adult patients who were admitted to AUH with proximal femoral fractures within one year.

We will evaluate the real treatment protocol which was applied for those patients.

Surgical procedures, as plating, Proximal Femoral Nail , Dynemic Hip screw and others procedures according to needed for each types.

This epidemological study in proximal femoral fractures will provide an update on incidence, admission, hospital stay and surgical procedures. This information will assist health providers in planning hospital beds, surgical intervention, and risk prevention, moreover, this data can be use for farther clinical studies.

Eligibility Criteria:
Inclusion Criteria:

* 1-Adult Age 2- Closed \& Open fracture

Exclusion Criteria:

* 1- Childern 2-pathological fractures
Prophylaxis Versus on Demand Treatment for Children With Hemophilia A

Comparison of the effect of three times a week prophylaxis on all bleeds with on-demand treatment for children with severe Hemophilia A.


Eligibility Criteria:
Inclusion Criteria:

* Male, aged 2-16yrs
* Severe hemophilia A (\<1% FVIII:C \[Blood Clotting Factor VIII:C\] )
* Minimum of at least 50 documented ED (exposure day) prior to enrolment
* No measurable inhibitor activity at baseline and history of FVIII inhibitor antibody formation
* Parents or legal guardians document, sign, and date informed consent

Exclusion Criteria:

* Another bleeding disease that is different from hemophilia A
* Known hypersensitivity to the active substance, mouse or hamster protein
* Thrombocytopenia (platelet count \<100 000/mm3) based on previous medical records
Malaria Control : Improving Access to Prevention, Diagnostic and Care for Vulnerable Rural Communities

In the REACT 2 project, a consortium proposes to study in Burkina Faso and Côte d'Ivoire, the impact of a public health intervention in rural communities in order to improve access to malaria therapeutic and preventive arsenal for vulnerable populations (i.e. children, adolescents and pregnant women). The intervention relies on the implementation of mobile health workers to support community health workers.


Eligibility Criteria:
Inclusion Criteria:

* global population

Exclusion Criteria:

* absence of informed consent
Male Breast Cancer Summa Health System/Akron City Hospital Experience 1995-2007

The primary goal of this retrospective study is to evaluate the male breast cancer patient population at Summa Health System/Akron City Hospital over a period of 18 years and compare the findings to historical data.

The objectives are to:

* identify risk factors.
* evaluate stage and histology at the time of presentation.
* document treatment modalities and outcomes.
* analyze outcomes for comparison to historical data.


Eligibility Criteria:
Inclusion Criteria:

* Male breast cancer patients diagnosed and/or treated at Summa Health System/Akron City Hospital from the reference year of 1995 through 2007.